Investor Overview

Overview

Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

8-K View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A View HTML

Additional proxy soliciting materials - definitive

DEFA14A View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.